Switching from natalizumab to fingolimod
نویسندگان
چکیده
منابع مشابه
Switching from Natalizumab to Fingolimod: Case Report and Review of Literature
Cite this article: Clark SJ, Wang Q, Mao-Draayer Y (2016) Switching from Natalizumab to Fingolimod: Case Report and Review of Literature. J Immunol Clin Res 3(1): 1030. *Corresponding author Yang Mao-Draayer, Department of Neurology, University of Michigan Medical School, 4015 A. Alfred Taubman Biomedical Sciences Research Building, 109 Zina Pitcher Place, Ann Arbor, Michigan 48109-2200, Tel: 7...
متن کاملSwitching from natalizumab to fingolimod: an observational study.
BACKGROUND Multiple sclerosis patients who discontinue using natalizumab are at risk of a rebound in disease activity. However, the optimal alternative therapy is not currently known. AIMS OF THE STUDY We report on clinical and MRI data and patient safety in a group of relapsing-remitting multiple sclerosis patients who tested seropositive for the JC virus and who have switched from natalizum...
متن کاملAssessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
BACKGROUND In light of the increased risk of progressive multifocal encephalopathy (PML) development under long-term treatment with the monoclonal antibody natalizumab which is approved for treatment of active relapsing remitting multiple sclerosis (RRMS), there is a clear need for alternative treatment options with comparable efficacy and reduced PML risk. One such option is fingolimod, a func...
متن کاملSafety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.
OBJECTIVE To assess safety of the switch between natalizumab and fingolimod without a washout period. METHODS Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. RESULTS After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events ...
متن کاملSafety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients
BACKGROUND In Poland, natalizumab or fingolimod treatment can be delivered as a second-line therapy to those patients with relapsing-remitting multiple sclerosis (RRMS) who demonstrated no response to interferon or glatiramer acetate treatment for a minimum of one year. MATERIAL AND METHODS Analysis covered 44 RRMS patients switched from first- to second-line therapy. The annualized relapse rat...
متن کاملProgressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
Background. Natalizumab- (NTZ-) associated progressive multifocal leukoencephalopathy (PML) is a severe and often disabling infectious central nervous system disease that can become evident in multiple sclerosis (MS) patients after NTZ discontinuation. Recently, novel diagnostic biomarkers for the assessment of PML risk in NTZ treated MS patients such as the anti-JC virus antibody index have be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 85 شماره
صفحات -
تاریخ انتشار 2015